Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 8/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3759745 | 0.91 | SRC (0.51) | SRCALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL3759750 | 0.83 | SRC (0.50) | SRCALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL3759748 | 0.83 | SRC (0.50) | SRCALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL12050503 | 0.83 | ALDH1A1 (0.53) | SRCALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL12050506 | 0.82 | SRC (0.49) | SRCALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL14782111 | 0.77 | SRC (0.48) | SRCALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL3325640 | 0.76 | ALDH1A1 (0.48) | SRCALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL3326580 | 0.75 | SRC (0.47) | SRCALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL3325844 | 0.74 | SRC (0.57) | SRCALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL3326237 | 0.74 | SRC (0.48) | SRCALDH1A1LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024074604-A1 | COMPOUNDS FOR THE MANAGEMENT OF CELL STEMNESS AND INVASION IN CANCER AND RELATED DISEASES | INSTITUTO BIOMAR, S.A (ES) | 2024-04-11 | — | — | WO | disclosed |
| EP-4349409-A1 | COMPOUNDS FOR THE MANAGEMENT OF CELL STEMNESS AND INVASION IN CANCER AND RELATED DISEASES | Instituto Biomar S.A. (ES) | 2024-04-10 | — | — | EP | disclosed |
| EP-3898613-B1 | ANTICANCER COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-09 | — | — | EP | disclosed |
| US-20220056021-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2022-02-24 | — | — | US | disclosed |
| EP-3898613-A1 | ANTICANCER COMPOUNDS | Pharma Mar S.A. (ES) | 2021-10-27 | — | — | EP | disclosed |
| US-20210317490-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A., (ES) | 2021-10-14 | — | — | US | disclosed |
| WO-2020127194-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2020-06-25 | — | — | WO | disclosed |
| US-20200140450-A1 | CHEMICAL METHOD OF PRODUCING SMTP GROUPS OR SMTP-7 AND INTERMEDIATES USED IN THE METHOD | SHOWA UNIVERSITY (JP) | 2020-05-07 | — | — | US | disclosed |
| US-10414745-B2 | Phenol derivatives to treat cancer | FUNDACIÓN MEDINA. CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA (ES) | 2019-09-17 | — | — | US | disclosed |
| WO-2018167270-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2018-09-20 | — | — | WO | disclosed |
| US-20100280108-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2010-11-04 | — | — | US | disclosed |
| EP-2231633-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2010-09-29 | — | — | EP | disclosed |
| EP-2231590-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2010-09-29 | — | — | EP | disclosed |
| US-20100196811-A1 | HIGHLY DISPERSE METAL OXIDES HAVING A HIGH POSITIVE SURFACE CHARGE | WACKER CHEMIE AG (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100048690-A2 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2010-02-25 | — | — | US | disclosed |
| US-20090186938-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-07-23 | — | — | US | disclosed |
| WO-2009080761-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080769-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-07-02 | — | — | WO | disclosed |
| EP-2032551-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007144423-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414745-B2 | Phenol derivatives to treat cancer | RB1, TP53, NCOR1 | SRC 654/4885ALDH1A1 454/4885LMNA 3155/4885 |
| US-20100048690-A2 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | RPLP1, PKD1, KRAS | SRC 2515/4885ALDH1A1 1692/4885LMNA 1728/4885 |
| US-20210317490-A1 | ANTICANCER COMPOUNDS | SLC75A1, SLC15A1, LCT | SRC 3014/4885ALDH1A1 947/4885LMNA 1138/4885 |
| US-20200140450-A1 | CHEMICAL METHOD OF PRODUCING SMTP GROUPS OR SMTP-7 AND INTERMEDIATES USED IN THE METHOD | TST, SMS, TMSB4X | SRC 2225/4885ALDH1A1 3911/4885LMNA 1028/4885 |
| US-20220056021-A1 | ANTICANCER COMPOUNDS | TP53, MCL1, MYC | SRC 2396/4885ALDH1A1 796/4885LMNA 1756/4885 |
| US-20090186938-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | RPLP1, PKD1, KRAS | SRC 2515/4885ALDH1A1 1692/4885LMNA 1728/4885 |
| US-20100280108-A1 | Antitumoral Compounds | TPD52L2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53 | SRC 2723/4885ALDH1A1 1599/4885LMNA 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.